By simultaneously disabling ERBB-mediated signaling and mitotic control via AURK inhibition, the afatinib/tozasertib combination effectively suppresses key survival pathways, offering a compelling rationale for clinical evaluation as a strategy to enhance the durability of responses and improve outcomes in KRAS mutant lung adenocarcinoma. Here, KRAS is linked to lung adenocarcinoma.